Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Tests JAB-21822 with JAB-3312 for advanced lung cancer with KRAS G12C

Tests JAB-21822 and JAB-3312 against standard treatment in adults with advanced lung cancer.

Key facts

Who runs it
Allist Pharmaceuticals, Inc.
Where
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Jilin City, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi’an, and Zhengzhou, ChinaSee the 37 sites
Trial code
Registry title
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Status
Recruiting
Phase
Phase 3
People taking part
392 people, planned
Started
7 Aug 2024
Expected to end
Aug 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • JAB-21822
  • Tislelizumab
  • JAB-3312
  • Pemetrexed
  • Carboplatin
Record updated
13 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-squamous non-small cell lung cancer that has a KRAS p.G12C mutation and has not yet been treated with systemic anticancer therapy.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced or metastatic non-squamous non-small cell lung cancer that cannot be removed by surgery, with at least one measurable tumour (RECIST 1.1). ECOG 1 or lower. Expected survival of 3 months or more.
Earlier treatment
No earlier systemic anticancer therapy for the locally advanced or metastatic disease.
Biomarker or test result
KRAS p.G12C mutation, confirmed by the central lab.

Main reasons for not taking part

  • Other solid or blood cancers within the past 2 years or at present
  • Other driver gene mutations with an available targeted therapy, or other KRAS mutations
  • Untreated central nervous system (CNS) metastases
  • Uncontrolled fluid around the lungs, heart or in the belly (pleural effusion, pericardial effusion, ascites)
  • Impaired heart function or significant heart disease

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • A signed written informed consent is required before performing any study-related operations
  • Age greater than or equal to 18 years old
  • Histologically or cytologically confirmed locally advanced/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab
  • No history of systemic anticancer therapy to the local advanced/metastatic disease
  • Expected survival period greater than or equal to 3 months
  • Having at least one target lesion according to RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) ≤ 1

Who cannot take part

  • Previous (≤2 years) or current solid tumors or hematologic tumors of other pathological types
  • Carry other driver gene mutations with available target therapy, or carry other KRAS mutations
  • Subjects with impaired heart function or clinically significant heart disease
  • Subjects with untreated central nervous system (CNS) metastases were excluded
  • Uncontrolled pleural effusion, pericardial effusion, and ascites

Where in China

  • Beijing Cancer HospitalBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • Beijing chest hospital, Capital Medical UniversityBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • Beijing Tiantan Hospital, Captal Medical UniversityBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Cancer Hospital, Chinese Academy of Medical SciencesBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • Pecking Union Medical College HospitalBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Peking University Third HospitalBeijing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • Cangzhou Hospital of Integrated TCM-WM·HebeiCangzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • Hunan Cancer HospitalChangsha, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Sichuan Province Cancer HospitalChengdu, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Fujian Cancer HospitalFuzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Harbin Medical University Cancer Hospital-Mammary gland of internalHaerbin, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The Second Affiliated Hospital Zhejiang School of MedicineHangzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Anhui Province cancer hospitalHefei, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Jilin Cancer HospitalJilin City, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shandong Cancer HospitalJinan, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdTaking people
  • LinYi Cancer HospitalLinyi, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Jiangsu Province HospitalNanjing, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Guangxi Medical University Cancer hospital & Guangxi Cancer InstituteNanning, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The Affiliated Hospital of Qingdao UniversityQingdao, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Fudan University Shanghai Cancer CenterShanghai, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shanghai Pulmonary HospitalShanghai, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Liaoning Cancer Hospital & InstituteShenyang, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The First Hospital of China Medical UniversityShenyang, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen CenterShenzhen, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Shanxi Province Cancer HospitalTaiyuan, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Taizhou Hospital, Zhejiang ProvinceTaizhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Hubei Cancer HospitalWuhan, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Tongji Hospital Tongji Medical College of HustWuhan, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Wuxi People's HospitalWuxi, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • Henan Cancer HospitalZhengzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting
  • The First Affiliated Hosipital Of Zhengzhou UniversityZhengzhou, ChinaContact: Shanghai Allist Pharmaceuticals Co., LtdNot yet recruiting

About the trial

What the trial wants to find out

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

The 2 groups in the trial

  • JAB-21822+JAB-3312Treatment being tested

    JAB-21822 tablet, 21 days as a treatment cycle; JAB-3312 tablet/capsule, 21 days as a treatment cycle

    Treatment: JAB-21822 and JAB-3312

  • Tislelizumab combined with Pemetrexed + CarboplatinExisting treatment, for comparison

    Tislelizumab injection, 21 days as a treatment cycle; Pemetrexed injection, 21 days as a treatment cycle; Carboplatin injection, 21 days as a treatment cycle

    Treatment: Tislelizumab, Pemetrexed, and Carboplatin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Plain-language title
Tests JAB-21822 with JAB-3312 for advanced lung cancer with KRAS G12CGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 August 2026